Simulations Plus, Inc. (NASDAQ:SLP) Stock Position Increased by Jones Financial Companies Lllp

Jones Financial Companies Lllp lifted its position in Simulations Plus, Inc. (NASDAQ:SLP) by 53.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,223 shares of the technology company’s stock after buying an additional 427 shares during the period. Jones Financial Companies Lllp’s holdings in Simulations Plus were worth $34,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of SLP. Conestoga Capital Advisors LLC raised its stake in shares of Simulations Plus by 15.0% in the 4th quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock worth $62,090,000 after buying an additional 290,414 shares in the last quarter. Tributary Capital Management LLC raised its stake in shares of Simulations Plus by 21.7% in the 4th quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company’s stock worth $11,047,000 after buying an additional 70,526 shares in the last quarter. Stephens Inc. AR acquired a new stake in shares of Simulations Plus during the fourth quarter worth $905,000. BNP Paribas Financial Markets raised its position in shares of Simulations Plus by 402.9% during the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock worth $1,279,000 after purchasing an additional 32,002 shares during the period. Finally, State Street Corp raised its position in shares of Simulations Plus by 4.7% during the third quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after purchasing an additional 28,953 shares during the period. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Trading Up 0.6 %

NASDAQ:SLP opened at $25.51 on Thursday. The firm has a market capitalization of $512.55 million, a price-to-earnings ratio of 63.78 and a beta of 0.89. Simulations Plus, Inc. has a 1-year low of $24.00 and a 1-year high of $51.22. The business’s fifty day moving average price is $31.42 and its 200 day moving average price is $31.03.

Insider Activity at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the transaction, the director now directly owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 19.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. KeyCorp boosted their target price on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $49.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.